Prostate Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

The prostate gland — a walnut-sized exocrine gland at the base of the bladder in men — is involved in three of the most common urological conditions: benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. BPH is a non-malignant enlargement of the prostate's transitional zone, compressing the urethra and causing lower urinary tract symptoms (LUTS): urinary frequency, urgency, nocturia, weak stream, straining, and incomplete emptying. Histological BPH is present in 50% of men aged 50–60 and over 90% aged over 80, though clinically significant LUTS requiring treatment affect approximately 25–30% of men over 60. Prostatitis encompasses a spectrum of prostate inflammatory conditions: acute bacterial prostatitis (ABP — febrile urinary infection with pelvic/perineal pain), chronic bacterial prostatitis (CBP — recurrent symptomatic UTIs from prostatic bacterial reservoir), chronic pelvic pain syndrome (CPPS — the most common prostatitis category, accounting for 90%, without demonstrable infection), and asymptomatic inflammatory prostatitis. Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men globally, with over 1.4 million new cases and 375,000 deaths annually. It spans a wide clinical spectrum — from indolent, slow-growing tumours that may never cause symptoms (Gleason grade group 1, the majority of screen-detected cancers) to aggressive, rapidly progressive disease requiring urgent multimodality treatment. Management ranges from active surveillance (monitoring without treatment) for low-risk localised disease to surgery, radiation, and systemic hormone therapy for more advanced stages. PSA (prostate-specific antigen) screening — a blood test measuring PSA concentration — enables early detection when cancer is localised and most treatable, but overdiagnosis of clinically insignificant cancer and overtreatment are important concerns that have shaped evidence-based screening guidelines.

Benign prostatic hyperplasia (BPH) causes bladder outlet obstruction leading to voiding and storage LUTS. Severity is quantified by the International Prostate Symptom Score (IPSS — 0 to 35; mild 1–7, moderate 8–19, severe 20–35), flow rate (Qmax below 10 mL/s suggests significant obstruction), post-void residual volume, and prostate volume (estimated by TRUS or MRI). Medical treatment is first-line for moderate symptoms: alpha-blockers (tamsulosin, alfuzosin, silodosin, doxazosin) relax prostate smooth muscle, improving Qmax and IPSS within days. 5-alpha-reductase inhibitors (5-ARIs — finasteride 5 mg, dutasteride 0.5 mg) reduce prostate volume by 20–30% over 6–12 months, preventing urinary retention and reducing the need for surgery in men with large prostates (above 40 mL). Combination therapy (alpha-blocker plus 5-ARI) is superior to either agent alone for long-term symptom control and urinary retention prevention. PDE5 inhibitor tadalafil (5 mg daily) is approved for LUTS-BPH in men without significant hypotension, with dual benefit if erectile dysfunction coexists. Prostatitis: ABP requires urgent hospitalisation, IV antibiotics (fluoroquinolone or aminoglycoside plus beta-lactam), and transurethral catheter or suprapubic drainage for urinary retention from inflamed prostate. CBP responds to 4–6 weeks of oral fluoroquinolone (ciprofloxacin, levofloxacin) with 60–80% symptom improvement. CPPS is managed with alpha-blockers (reducing pelvic smooth muscle tension), 5-ARIs, NSAIDs, pelvic floor physiotherapy, and psychological support. Prostate cancer: active surveillance for low-risk disease monitors PSA kinetics, multiparametric MRI, and periodic biopsy without immediate treatment. Curative intent options for localised disease: radical prostatectomy (surgical) or radiation (external beam IMRT or brachytherapy). Locally advanced and metastatic disease: androgen deprivation therapy (ADT — LHRH agonists: leuprolide, goserelin; or antagonists: degarelix, relugolix) plus novel antiandrogens (abiraterone, enzalutamide, darolutamide, apalutamide).

BPH evaluation: IPSS questionnaire, flow rate study (uroflowmetry), post-void residual ultrasound, serum PSA (to exclude prostate cancer in men with voiding symptoms), renal function, and urinalysis. Men with IPSS 8 or above with bother are candidates for medical therapy. Those failing medical therapy or with absolute surgical indications (urinary retention, recurrent UTIs, bladder stones, renal impairment from obstruction) are referred for surgical management. Prostate cancer screening: PSA testing is individualised — shared decision-making discusses benefits of early detection and harms of overdiagnosis. PSA above 4 ng/mL or rising PSA velocity above 0.75 ng/mL/year prompts multiparametric MRI prostate (mpMRI — PI-RADS scoring system, 1–5) and then targeted biopsy of PI-RADS 3–5 lesions combined with systematic 12-core transrectal or transperineal biopsy. MRI-fusion targeted biopsy improves cancer detection and reduces diagnosis of insignificant cancer. Risk stratification after biopsy: Gleason grade group (1–5), clinical stage (cT category), number and percentage of cores positive, and PSA level define low-, intermediate-, and high-risk categories that guide management. Bone scan (isotope scintigraphy) and PSMA PET-CT are indicated for PSA above 20 ng/mL, Gleason grade group 4–5, or clinical T3–T4 disease to detect nodal and bone metastases. ADT eligibility: bilateral orchidectomy or LHRH agonist/antagonist therapy achieves castrate testosterone levels (below 50 ng/dL or 1.7 nmol/L) and is the backbone of metastatic prostate cancer treatment.

BPH medical therapy is first-line: alpha-blockers (tamsulosin 0.4 mg daily, alfuzosin 10 mg daily, doxazosin 4–8 mg daily) improve urinary flow and reduce IPSS by 4–6 points within 2–4 weeks. 5-ARIs (finasteride 5 mg or dutasteride 0.5 mg daily) reduce prostate volume by 20–30% and reduce acute urinary retention risk by 57% over 2–4 years (MTOPS trial) — best for prostates above 40 mL or PSA above 1.5 ng/mL. For prostate cancer, active surveillance (AS) is the recommended management for PRIAS low-risk criteria (PSA below 10, grade group 1, cT1–T2a, no more than 2 positive cores) — monitoring with PSA every 3–6 months, mpMRI every 12–24 months, and repeat biopsy at 1 year and then every 2–3 years. Active treatment triggers: PSA doubling time below 3 years, upgrading on biopsy (grade group 2+), or patient preference. Radical prostatectomy: robot-assisted (RARP) or open retropubic radical prostatectomy removes the entire prostate, seminal vesicles, and pelvic lymph nodes — curative for localised disease; appropriate for all risk groups with life expectancy over 10 years. External beam radiotherapy (EBRT): intensity-modulated radiotherapy (IMRT) with image guidance (IGRT) delivers 74–78 Gy to the prostate over 7–8 weeks; stereotactic body radiotherapy (SBRT) delivers 36–40 Gy in 5 fractions. Both achieve equivalent cancer control to surgery for localised disease. Brachytherapy: permanent low-dose rate (LDR) seed implants (iodine-125, palladium-103) for low-risk; temporary high-dose rate (HDR) brachytherapy boost for intermediate-risk combined with EBRT. For advanced/metastatic disease: ADT backbone (LHRH agonist or antagonist) combined with docetaxel chemotherapy or novel hormone agents (abiraterone acetate + prednisolone, enzalutamide, apalutamide, darolutamide) depending on metastatic burden and prior treatment. Lutetium-PSMA-617 (lutetium vipivotide tetraxetan — Pluvicto) radioligand therapy targets PSMA-expressing prostate cancer cells and is approved for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after ADT and docetaxel.

Alpha-blocker monotherapy improves IPSS by 4–6 points and Qmax by 1.5–3 mL/s within 4–6 weeks in 60–70% of men, with rapid onset of symptom relief. Combined alpha-blocker plus 5-ARI (CombAT trial: dutasteride + tamsulosin) reduces acute urinary retention risk by 68% and surgical intervention risk by 71% at 4 years versus placebo, while providing superior symptom improvement to either agent alone. Active surveillance for low-risk prostate cancer avoids or substantially delays treatment-related side effects (erectile dysfunction, incontinence) in men who may never need intervention — 15-year cancer-specific survival exceeds 97% for Gleason grade group 1 disease. Radical prostatectomy and radiotherapy achieve equivalent 10-year overall survival for localised prostate cancer in multiple randomised trials (ProtecT trial, 2023 update); both provide over 95% 10-year cancer-specific survival for low- and intermediate-risk disease. ADT combined with abiraterone or enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC) improves overall survival by 35–40% versus ADT alone (LATITUDE, ENZAMET, ARCHES trials). PSMA PET-CT has revolutionised prostate cancer staging, detecting recurrence at PSA levels as low as 0.2 ng/mL and identifying oligometastatic disease amenable to stereotactic ablative radiotherapy (SABR) with survival benefit.

Alpha-blocker side effects: orthostatic hypotension (particularly doxazosin and terazosin — start at low dose, increase gradually), retrograde ejaculation (30–90% with tamsulosin and silodosin, less with alfuzosin), and intraoperative floppy iris syndrome (IFIS) — alpha-blockers must be discontinued before cataract surgery. 5-ARI side effects: decreased libido (5–10%), erectile dysfunction (5–8%), ejaculatory disorders, and a rare post-finasteride syndrome of persistent sexual and neuropsychiatric symptoms (controversial but reported). 5-ARIs lower PSA by approximately 50% at 6 months — this must be accounted for when interpreting PSA for cancer screening. Radical prostatectomy risks: urinary stress incontinence (10–30% at 12 months, most recovering with physiotherapy), erectile dysfunction (40–70% depending on nerve-sparing — improving over 18–24 months), anastomotic stricture (5–8%), lymphocele (2–5% after extended lymph node dissection). Radiotherapy side effects: acute proctitis and cystitis during treatment (Grade 2 in 20–30%); late rectal bleeding from radiation proctopathy (3–5%); late urinary incontinence less common than after surgery; late erectile dysfunction developing over 2–3 years due to radiation injury to cavernous nerves (40–60% at 3 years). ADT side effects are substantial and cumulative: hot flushes (60–80%), fatigue, muscle mass loss (sarcopenia), osteoporosis (bone density loss 2–5% per year — bisphosphonate or denosumab prophylaxis required), metabolic syndrome, insulin resistance, cardiovascular disease acceleration, cognitive decline, and depression.

BPH follow-up: clinical assessment with IPSS and uroflowmetry at 4–6 weeks after starting medical therapy, then 6–12 monthly. PSA monitoring (accounting for 5-ARI-induced 50% reduction at 6 months) continues annually to detect prostate cancer. After radical prostatectomy: PSA every 3–6 months for 2 years (target undetectable, below 0.1 ng/mL at 6–8 weeks), then 6-monthly to 5 years, then annually. Rising PSA (biochemical recurrence — two readings above 0.2 ng/mL) prompts PSMA PET-CT to localise disease and consideration of salvage radiotherapy (to the prostatic bed, ideally when PSA below 0.5 ng/mL) with or without short-course ADT. After radiotherapy: PSA nadir plus 2 ng/mL (Phoenix definition) defines biochemical failure after EBRT — typically at PSA nadir of 0.5–1.5 ng/mL. PSA monitored every 6 months. After ADT: PSA every 3–6 months; testosterone level confirms castration (below 50 ng/dL); bone density (DEXA) at baseline and annually; metabolic panel for cardiovascular risk. Progression to castration-resistant prostate cancer (CRPC — PSA rising on castrate testosterone) triggers next-line therapy selection based on metastatic burden, prior treatment history, and molecular profile (homologous recombination repair mutations — BRCA1/2 — identify PARP inhibitor eligibility: olaparib, rucaparib).

BPH medical therapy (tamsulosin or finasteride generic): India USD 3–10/month; USA USD 20–80/month. Alpha-blocker plus 5-ARI combination: India USD 10–20/month; USA USD 100–400/month brand. Prostate cancer evaluation (PSA, mpMRI, biopsy): India USD 300–800; USA USD 1,500–5,000. RARP (robotic radical prostatectomy): India USD 6,000–15,000; Thailand USD 12,000–25,000; USA USD 25,000–60,000; UK GBP 15,000–35,000. EBRT (IMRT course): India USD 5,000–15,000; Thailand USD 10,000–20,000; USA USD 25,000–80,000. Brachytherapy (LDR seeds): India USD 4,000–10,000; USA USD 15,000–35,000. ADT (LHRH agonist injection, e.g. leuprolide — monthly): India USD 100–300 per injection; USA USD 1,000–2,000 per injection brand. Novel androgen receptor pathway inhibitors (enzalutamide, abiraterone — monthly): India USD 500–2,000 (generic access programs); USA USD 5,000–12,000. Lutetium-PSMA therapy (per cycle): India USD 5,000–10,000; USA USD 20,000–42,000. Medical tourism to India for prostate cancer treatment — radiation or radical prostatectomy — saves 60–80% versus USA pricing at JCI-accredited oncology centres including Tata Memorial, Apollo Cancer Centre, and Fortis.

For BPH, phytotherapy agents — saw palmetto extract (Serenoa repens), pygeum africanum, and beta-sitosterol — have modest but inconsistent evidence from clinical trials, with lower efficacy than pharmaceutical options but minimal side effects; they are appropriate for men preferring natural approaches with mild symptoms. Prostate artery embolisation (PAE) — an interventional radiology procedure selectively embolising prostate arteries to reduce prostatic blood supply and volume by 15–30% — provides a surgical alternative for men with high surgical risk or ejaculatory function priority. For prostate cancer, focal therapy (HIFU to the index lesion, cryotherapy, focal laser ablation, vascular-targeted photodynamic therapy) targets only the dominant cancer within the prostate, avoiding treatment of the entire gland and reducing side effects — medium-term cancer control data support its use in selected very-low-risk and low-risk disease at high-volume centres. For metastatic hormone-sensitive disease, triplet therapy (ADT plus docetaxel plus abiraterone — PEACE-1 trial) further improves overall survival over doublet therapy in high-volume disease. Radium-223 (Xofigo) targets bone metastases specifically in mCRPC with bone metastases, improving overall survival with minimal haematological toxicity. Pembrolizumab (anti-PD-1) is approved for mismatch repair-deficient (MSI-high) prostate cancer — a rare but highly immunotherapy-responsive subgroup identified by tumour molecular profiling.